Template:Ergotamine: Difference between revisions
Jump to navigation
Jump to search
(Created page with "{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; ! style="padding: 0 5px; font-size: 100%; background:#F8F8...") |
No edit summary |
||
| Line 3: | Line 3: | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | ERGOMAR (ergotamine tartrate) tablet<sup>®</sup> FDA Package Insert | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | ERGOMAR (ergotamine tartrate) tablet<sup>®</sup> FDA Package Insert | ||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine indications and usage|Indications and Usage]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine dosage and administration|Dosage and Administration]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine dosage forms and strengths|Dosage Forms and Strengths]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine contraindications|Contraindications]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine warnings and precautions|Warnings and Precautions]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine adverse reactions|Adverse Reactions]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine drug interactions|Drug Interactions]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine use in specific populations|Use in Specific Populations]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine overdosage|Overdosage]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine description|Description]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine clinical pharmacology|Clinical Pharmacology]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine nonclinical toxicology|Nonclinical Toxicology]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine clinical studies|Clinical Studies]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine how supplied storage and handling|How Supplied/Storage and Handling]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine patient counseling information|Patient Counseling Information]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine labels and packages|Labels and Packages]] | |||
|- | |||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on Ergotamine | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} ClinicalTrials.gov] | |||
|-style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; | |||
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Ergotamine|{{fontcolor|#6C7B8B|Ergotamine}}]]''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | medihaler ergotamine (ergotamine tartrate) aerosol, metered [3M Riker] <sup>®</sup> FDA Package Insert | |||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine indications and usage|Indications and Usage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Ergotamine indications and usage|Indications and Usage]] | ||
Revision as of 02:23, 11 February 2014
| Ergotamine |
|---|
| ERGOMAR (ergotamine tartrate) tablet® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Dosage Forms and Strengths |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| Clinical Studies |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Ergotamine |
| ClinicalTrials.gov |
| Ergotamine |
| medihaler ergotamine (ergotamine tartrate) aerosol, metered [3M Riker] ® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Dosage Forms and Strengths |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| Clinical Studies |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Ergotamine |
| ClinicalTrials.gov |